![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
X
20
Cipla Limited Mumbai In, based in India, is a pharmaceutical company that stands out with its certifications from FDA, EDQM and WHO-GMP.
One of their significant offerings is Letrozole, supported by a 'Valid' Certificate of Suitability (CEP) with the number R1-CEP 2010-300 - Rev 00
This Chemical Type CEP, issued on July 08, 2019, remains in force until January 01, 1970, ensuring its reliability within the pharmaceutical industry.
Substance Number 2334 associated with this CEP further emphasizes